deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT02119156

Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients

An Open-label, Non-randomized, 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment With Belimumab 10 mg/kg in Systemic Lupus Erythematosus Subjects

Sponsor: GlaxoSmithKline

Conditions Systemic Lupus Erythematosus
Interventions Belimumab
Updated 16 times since 2017 Last updated: Jan 21, 2020 Started: May 13, 2014 Primary completion: Dec 14, 2018 Completion: Dec 14, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Systemic Lupus Erythematosus, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 16 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Oct 2017 · 4 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Feb 2020 · 12 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE3

▶ Show 11 earlier versions

  1. Feb 2020 — Jan 2021 [monthly]

    Completed PHASE3

  2. Feb 2019 — Feb 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Nov 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  8. Jun 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  9. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  10. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE3

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Chiba, Japan , Daegu, South Korea , Dallas, United States , Ehime, Japan , Hangzhou, China , Hefei, China , Hokkaido, Japan , Los Angeles, United States , Manhasset, United States and 6 more locations